Vibegron for the treatment of overactive bladder symptoms
US12357636B2 · kind B2 · utility
0Cited by
37References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 5, 2019 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | May 4, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to a method of treating overactive bladder symptoms in men with benign prostatic hyperplasia comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.